Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines
- Investment secures runway to reach cash flow positivity - NEEDHAM, Mass., July 14, 2026 /PRNewswire/ -- Mighty Therapeutics Holdings Inc. (the "Company" or "Mighty"), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial...
- Investment secures runway to reach cash flow positivity - NEEDHAM, Mass., July 14, 2026 /PRNewswire/ -- Mighty Therapeutics Holdings Inc. (the "Company" or "Mighty"), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.